Anti-angiogenic therapy: Adapting strategies to overcome resistant tumors-Reference-Cited by-同舟云学术

Anti-angiogenic therapy: Adapting strategies to overcome resistant tumors

Published:2010-07-12 Issue:3 Volume:111 Page:543-553
ISSN:0730-2312
Container-title:Journal of Cellular Biochemistry
language:en
Short-container-title:J. Cell. Biochem.

Author:

Mitchell Dianne C.,Bryan Brad A.

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcb.22764/fullpdf

Reference93 articles.

1. Murine Lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro;Allport;Neoplasia,2003

2. Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors;Annabi;J Cell Biochem,2004

3. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells;Barleon;Cancer Res,1997

4. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients;Batchelor;Cancer Cell,2007

5. Regulation of vascular permeability by vascular endothelial growth factors;Bates;Vascul Pharmacol,2002

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer;Frontiers in Immunology;2023-10-23

2. Artificial Nanoplatelets Depend on Size for Precisely Inducing Thrombosis in Tumor Vessels;Small Methods;2022-03-28

3. MTA1, a metastasis‑associated protein, in endothelial cells is an essential molecule for angiogenesis;Molecular Medicine Reports;2021-11-09

4. Epigenetic Regulation of Angiogenesis in Development and Tumors Progression: Potential Implications for Cancer Treatment;Frontiers in Cell and Developmental Biology;2021-09-06

5. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies;OncoTargets and Therapy;2021-05